Key Highlights

● Bicara shares fell steeply on heavy trading volume.

● The stock hit a new 52-week low.

● No company news or filing explained the drop.

● The company had $497.3 million in cash as of mid-2026.

Bicara Therapeutics (NASDAQ:BCAX) plunged in one of the steepest declines on the Russell 2000, but no company news was found to explain the move. The stock fell sharply on heavy volume, hitting a new 52-week low, with reports differing on the size of the decline at various points in the day.

A market live blog also said it found no company news behind the move, and Bicara had not issued a release or filing that accounted for the selloff in the reports available.

A Busy Day in Head and Neck Cancer

The session did bring major news from elsewhere in Bicara's field. Genmab rallied after reporting Phase 3 results showing that its experimental antibody, combined with a standard immunotherapy, cut the risk of death in head and neck cancer, meeting both primary endpoints of the trial.

No source tied Bicara's decline directly to that data, and investors will be watching for any comment from the company on the competitive landscape.

What Bicara Does

Bicara Therapeutics is a clinical-stage biotech developing treatments for solid tumors. Its lead program is being studied in head and neck squamous cell carcinoma, a cancer that affects tissues in the mouth, throat and voice box.

The company had $497.3 million in cash as of mid-2026, a figure closely watched by investors since it determines how long a development-stage biotech can fund its trials before needing to raise more money.